Development of cross-resistance by Aspergillus fumigatus to clinical azoles following exposure to prochloraz, an agricultural azole by Faria-Ramos, Isabel et al.
Faria-Ramos et al. BMC Microbiology 2014, 14:155
http://www.biomedcentral.com/1471-2180/14/155RESEARCH ARTICLE Open AccessDevelopment of cross-resistance by Aspergillus
fumigatus to clinical azoles following exposure to
prochloraz, an agricultural azole
Isabel Faria-Ramos1, Sofia Farinha1, João Neves-Maia1, Pedro Ribeiro Tavares1, Isabel M Miranda1,2,3,
Letícia M Estevinho4, Cidália Pina-Vaz1,2,3,5 and Acácio G Rodrigues1,2,3,6*Abstract
Background: The purpose of this study was to unveil whether azole antifungals used in agriculture, similar to the
clinical azoles used in humans, can evoke resistance among relevant human pathogens like Aspergillus fumigatus, an
ubiquitous agent in nature. Additionally, cross-resistance with clinical azoles was investigated. Antifungal susceptibility
testing of environmental and clinical isolates of A. fumigatus was performed according to the CLSI M38-A2 protocol. In
vitro induction assays were conducted involving daily incubation of susceptible A. fumigatus isolates, at 35°C and
180 rpm, in fresh GYEP broth medium supplemented with Prochloraz (PCZ), a potent agricultural antifungal, for a
period of 30 days. Minimal inhibitory concentrations (MIC) of PCZ and clinical azoles were monitored every ten days. In
order to assess the stability of the developed MIC, the strains were afterwards sub-cultured for an additional 30 days in
the absence of antifungal. Along the in vitro induction process, microscopic and macroscopic cultural observations
were registered.
Results: MIC of PCZ increased 256 times after the initial exposure; cross-resistance to all tested clinical azoles was
observed. The new MIC value of agricultural and of clinical azoles maintained stable in the absence of the selective
PCZ pressure. PCZ exposure was also associated to morphological colony changes: macroscopically the colonies
became mostly white, losing the typical pigmentation; microscopic examination revealed the absence of conidiation.
Conclusions: PCZ exposure induced Aspergillus fumigatus morphological changes and an evident increase of MIC
value to PCZ as well as the development of cross-resistance with posaconazole, itraconazole and voriconazole.
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The ubiquitous saprophytic mould Aspergillus fumigatus
is known to cause a spectrum of diseases in humans, in-
cluding allergic syndromes, noninvasive infections, and
invasive aspergillosis, a condition associated with signifi-
cant morbidity and mortality [1]. A. fumigatus is one of
the human pathogenic fungi that have a natural habitat
in the environment, including soil and plants [2]. Some
members of the azole drug class, which includes vorico-
nazole (VRC) and posaconazole (POS), have been shown* Correspondence: agr@med.up.pt
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article, unless otherwise stated.to be effective in the treatment of invasive aspergillosis
[3], and for a long time, azole resistance among clinical
A. fumigatus isolates was considered to be an uncommon
finding. However, multiazole resistance is emerging and is
increasingly recognized as a cause of treatment failure
[4,5]. In agriculture, thousands of tons of azoles are sold
annually for the purpose of plant protection, either to pre-
vent or to control fungal growth that can cause extensive
loss of crops or to ease the problem of postharvest
spoilage of plants and fruits [6]. The mechanism of ac-
tion of all azoles - irrespectively of their chemical struc-
ture and variable biological properties - is based on its
interference with the activity of fungal lanosterol 14
alpha-demethylase, an enzyme encoded by Cyp51A gene
in A. fumigatus that is responsible for the transformationntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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fungal cytoplasmatic membrane. The inhibition of ergos-
terol formation results in cell membrane disorganization
and impairment of fungal growth. Therefore, azoles are
considered fungistatic rather than fungicidal, and it is well
known that a strong and persistent antimicrobial pressure
can lead to the selection of resistant clones, particularly if
the drug effect is static rather than microbicidal [7]. Since
azoles are the mainstay treatment for both human and agri-
cultural fungal diseases, a major concern is the predictable
emergence of cross-resistance to clinical A. fumigatus iso-
lates that is already observed in several countries, driven by
the massive use of azole fungicides in agriculture, which
have the same mechanism of action as those used in
humans [7-11]. The aim of our study was to investigate
whether Prochloraz (PCZ), an azole extensively used in
agriculture, could be associated with the development of
cross-resistance to clinical azoles among A. fumigatus.
Results and discussion
The three isolates developed a progressive increment of
PCZ minimal inhibitory concentrations (MIC) value. In
addition, a concomitant increase of the MIC of VRC,
POS and Itraconazole (ITZ) was also observed (Table 1).
During the induction assay, MIC of PCZ increased 256
times from day 0 until day 30. Concerning the clinical
azoles, cross-resistance was developed since all isolates
changed from a susceptible to a resistant phenotype, ac-
cording to Meletiadis and colleagues [12].Table 1 Susceptibility pattern of tested A. fumigatus








PCZ VRC POS ITZ FLC
LMF05 0 0.125 0.125 0.25 2 >64
10 0.25 0.25 0.5 2 >64
20 8 2 1 4 >64
30 32 8 2 8 >64
Ø30 32 2 2 2 >64
LMF11 0 0.125 0.25 0.125 0.5 >64
10 0.125 2 0.25 1 >64
20 8 8 1 2 >64
30 32 >16 4 4 >64
Ø30 32 2 1 0.5 >64
LMN60 0 0.25 0.25 0.125 0.25 >64
10 4 8 0.25 1 >64
20 8 8 0.5 2 >64
30 64 >16 4 4 >64
Ø30 64 2 1 0.25 >64
PCZ, Prochloraz; VRC, Voriconazole; POS, Posaconazole; ITZ, Itraconazole; FLC,
Fluconazole; Ø, MIC after 30 days of culture in the absence of PCZ.There are several studies that have characterized azole
resistance in A. fumigatus, and most recently some ad-
dressed the possible cross-resistance between environmen-
tal and medical azoles [8-11]. Our study demonstrated the
time frame between the introduction of a widely used agri-
cultural antifungal and the emergence of cross-resistance to
medical triazoles. During the induction assay, we found that
besides the emergence of cross-resistance, PCZ exposure
caused marked morphological colony changes, both macro-
scopically and microscopically. Macroscopic modification
of the pigmentation of A. fumigatus colonies, changing
from the original green colour to white (Figure 1A, B
and C) was remarkable at the beginning of the assay.
With the increase of MIC values of PCZ the colonies be-
came scarcer, smaller and totally white (Figure 1C).
Microscopic examination showed a progressive absence of
conidiation: the original strain (Figure 1A) showed normal
microscopic features regarding conidiation (Figure 2A)
while almost white colonies (Figure 1B) showed nearly
complete absence of conidiation (Figure 2B). The totally
white mycelia (Figure 1C) corresponded solely to hyphae
and immature little conidiophore structures without co-
nidia (Figure 2C). These changes in pigmentation and in
conidiation as a consequence of exposure to azoles have
already been reported. Varanasi and colleagues speculate
that azoles may bind to a phytochrome-like regulatory
molecule inhibiting the initiation and subsequent develop-
ment of conidiophores in Aspergillus species [13]. Such
mechanism of action could also explain the different levels
of inhibition displayed by other tested azoles and why
echinocandins and polyenes did not show this effect [13].
Notably, such morphological changes may be responsible
for laboratorial diagnostic misidentification of the fungal
genus/species [14]. The high MIC values for PCZ that
were achieved in vitro maintained stable following re-
moval of the selective pressure of the drug. For VRC, the
MIC value decreased only after 30 days of incubation
without the selective pressure, changing the susceptibility
phenotype from resistant to intermediate. For POS, the
developed MIC value also decreased but not enough to
change the phenotype of resistance. Regarding ITZ, for
both LMF11 and LMN60, it was observed the complete
reversibility of the resistant phenotype in the absence of
PCZ, ie, the MIC reverted to the initial value (susceptible).
However, strain LMF05 had, since day zero, ITZ MIC of
2 mg/L, which falls in resistant category. In all the isolates
conidiation reappeared together with the typical green
colour of mature colonies following the removal of PCZ.
Since PCZ was responsible for the emergence of stable
resistance to itself and to very important medical tria-
zoles in A. fumigatus, a resistance mechanism may have
been developed. Previous reports describe cyp51A mu-
tation, efflux pump overexpression and/or target up-
regulation as the main mechanisms responsible for
Figure 1 Photographs of Sabouraud dextrose agar plates showing macroscopic morphological changes of colonies of A. fumigatus
following exposure to subinhibitory concentration of PCZ. A. Initial morphological aspect (control). B. After fifteen days. C. After thirty days.
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harbouring the TR34/L98H mutation has been re-
ported across several countries [15-18]. Interestingly,
besides the fact that these resistant isolates are less
genetically variable than susceptible ones, no impact
on fitness was observed [18]. The phenotypic results
(Figures 1 and 2) and the stability of the developed re-
sistance (Table 1) herein reported suggest the same.
Future studies aiming to assess the underlying molecu-
lar resistance mechanisms, not only from these in-
duced resistant strains but also from isolates with
naturally high MIC values to PCZ and resistant to
medical azoles without previous in vitro induction, will
certainly be our next step. Meanwhile, our study sug-
gests that the abuse of azole antifungals in nature may
cause serious human health problems since azole-
resistance and cross-resistance has the potential to fur-
ther compromise the efficacy of clinical azoles in the
future [4,17-20]. Furthermore, we can speculate that
the exposure of clinically relevant moulds other than
A. fumigatus to agricultural azoles may also be associ-
ated with the emergence of cross-resistance to clinical
azoles. Several compounds are being tested in order toFigure 2 Photomicrographs of Aspergillus fumigatus colonies using th
blue staining. Microscopic morphological changes in the development of
concentration of PCZ. A. Initial morphological aspect (control). B. After fiftefind new antifungal alternatives, anticipating the pos-
sible loss of efficacy of clinical azoles [21]. On the
other hand, efforts should be made to find safer com-
pounds to use in agriculture.
Conclusions
In order to assess the real dimension of Aspergillus re-
sistance, a susceptibility test should be performed in all
isolates from patients with Aspergillus infection. More-
over, for patients with severe infection initial combin-
ation therapy may be considered in geographical areas
with high prevalence of environmental azole resistant
isolates. Ultimately, surveillance studies in both clinical
and in environment settings should be conducted in




Two clinical isolates of A. fumigatus, LMF05 and LMF11,
and one environmental A. fumigatus isolate (LMN60, re-
covered from a garden nearby the hospital), were used in
this study. The isolates were identified as belonging to A.e cellotape flag technique preparation with lactophenol cotton
conidiation of A. fumigatus following exposure to subinhibitory
en days. C. After thirty days.
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morphology, the ability to grow at 48°C and by using
MALDI-TOF MS to accurately discriminate A. fumigatus
from a new sibling species A. lentulus, which cannot be
distinguished by morphological characteristics or growth
peculiarities [22]. Long-term preservation of conidial sus-
pensions of the isolates was made in a GYEP medium (2%
glucose, 0.3% yeast extract, 1% peptone) broth supple-
mented with 10% glycerol and stored at −80°C. Working
cultures were subsequently maintained during 2 weeks on
Sabouraud dextrose agar slants and plates at 4°C.
Antifungal agents and susceptibility profile
PCZ is an imidazole and one of the main drugs used
within European Union for crop protection [23]. This er-
gosterol biosynthesis inhibitor was selected as a repre-
sentative of agricultural azoles after a previous MIC
screening, where it showed to be the less active agricul-
tural drug on the selected strains, ie, it had the lower
MIC values, which was a prerequisite for this induction
experiment. Fluconazole (FLC), VRC, POS and ITZ were
selected as clinical azoles. PCZ was ressuspended in 80%
acetone solution at a final concentration of 5 mg/L. Clin-
ical azoles were dissolved in dimethysulphoxide (DMSO)
to obtain stock solutions of 10 mg/L. All drugs were
stored at -20°C. Broth microdilution susceptibility assay
was performed according to the Clinical and Laboratory
Standards Institute M38-A2 protocol in order to evalu-
ate the initial MIC of PCZ and of all the clinical azoles
[24]. Drug concentration ranged from 0.125 to 64 mg/L
of FLC and PCZ; and 0.0313 to 16 mg/L of POS, VRC
and ITZ. A. fumigatus ATCC 46645 was included for
quality control of susceptibility testing. Also, FLC was
used as control, since A. fumigatus shows a non-susceptible
phenotype and MIC is most often above 64 mg/L for this
species. MIC of azoles was defined as the lowest concentra-
tion of the drug that produced no visible growth following
48 hours of incubation. MIC determination was repeated at
least twice.
In vitro induction experiments
Induction experiments were performed with the agricul-
tural azole PCZ. A. fumigatus isolates were grown on
Saboraud dextrose agar at 35°C for 72 h; conidia were
harvested by flooding the surface of the slants with
phosphate-buffered saline (PBS) containing 0.025% (vol/
vol) tween 80 while gently rocking. The conidial suspen-
sions were then adjusted using specific spectrophoto-
metric readings at 550 nm to a final concentration of
5×104 conidia per militer [25]; one militer of each dis-
tinct isolate suspension was transferred to 9 ml of GYEP
broth supplemented with sub-inhibitory concentrations
of PCZ (0.06 mg/L for both LMF05 and LMF11;
0.125 mg/L for LMN60) and incubated overnight at35°C with agitation (180 rpm). Daily, after vigorous vor-
texing for 60 seconds, one militer from each culture was
transferred to fresh GYEP medium supplemented with
PCZ and in parallel, 1 ml of culture was added with 10%
glycerol and frozen at -80°C. This procedure was re-
peated along thirty consecutive days.
Susceptibility testing/ Stability of in vitro developed
resistance phenotype
MICs of PCZ were determined every ten days along the
thirty days of induction assay. No official breakpoints
are yet defined for PCZ; therefore, whenever a marked
MIC increase was observed (four fold the initial PCZ
MIC), the MIC values of clinical antifungals were
determined.
In order to assess the stability of the developed MIC
increment to PCZ and of the developed cross-resistance
to clinical azoles, the induced strains were afterwards
sub-cultured for an additional thirty days in the absence
of the drug and MIC values re-determined, as previously
described.
Culture macro and micro morphology
Along the induction process, every two days, a loopful
was inoculated in Saboraud Agar slants to check for via-
bility and purity of culture. Macro and microscopical
growth characteristics were registered. Colony morph-
ology and pigmentation were recorded photographically
using a Reflex Nikon D3200 Camera and images were
processed by Adobe Photo Deluxe Image Processing
Program. Microscopic images of hyphae changes from
the original A. fumigatus strain and from the resistant
induced strain were captured with a Zeiss-Axioplan-2
microscope equipped with Axio Cam. AxioVision 3.0
digital imaging software was used for editing.
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